Related Experiment Videos
Endocrine plus uracil/tegafur therapy for prostate cancer
Y Ono1, S Ohshima, Y Takahashi
1Department of Urology, Nagoya University School of Medicine, Japan.
Oncology (Williston Park, N.Y.)
|August 12, 1999
Summary
Adding uracil and tegafur (UFT) to endocrine therapy showed a trend toward improved outcomes in prostate cancer patients. While not statistically significant, the UFT combination demonstrated higher progression-free survival and 5-year survival rates.
Area of Science:
- Oncology
- Clinical Pharmacology
- Urology
Background:
- Prostate cancer management often involves endocrine therapy.
- Novel combination therapies are explored to enhance treatment efficacy.
- Uracil and tegafur (UFT) is an oral fluoropyrimidine with potential anticancer activity.
Purpose of the Study:
- To evaluate the efficacy and tolerability of adding UFT to endocrine therapy for prostate cancer.
- To compare outcomes between patients receiving endocrine therapy plus UFT versus endocrine therapy alone.
Main Methods:
- A prospective, randomized clinical trial involving 136 prostate cancer patients.
- Two arms: endocrine therapy + UFT (69 patients) vs. endocrine therapy alone (67 patients).
- Mean follow-up: 54.9 months (UFT group) and 47.8 months (endocrine-only group).
Main Results:
- Disease progression-free rates: 53.0% (UFT group) vs. 43.8% (endocrine-only group) (P = .114).
- 5-year cancer-specific survival: 67.4% (UFT group) vs. 49.5% (endocrine-only group) (P = .273).
- 5-year overall survival: 47.4% (UFT group) vs. 35.4% (endocrine-only group) (P = .177).
- Adverse effects were comparable between groups and not specifically linked to UFT.
Conclusions:
- Endocrine chemotherapy combined with UFT is a tolerable regimen for prostate cancer patients.
- The combination therapy showed a trend towards improved disease control and survival, warranting further investigation.
- UFT may offer a beneficial addition to standard endocrine treatment for prostate cancer.